other material
confidence high
sentiment positive
materiality 0.85
Delcath: Q3 prelim rev $20.5M, net income $0.8M; CHOPIN trial meets endpoint
DELCATH SYSTEMS, INC.
- Prelim Q3 rev $20.5M ($19.2M HEPZATO, $1.3M CHEMOSAT); net income $0.8M; adj EBITDA $5.3M; cash $88.9M, no debt.
- FY2025 rev guidance raised to $83-85M, reflecting ~150% treatment volume increase over 2024.
- CHOPIN trial met primary endpoint: 1-yr PFS 54.7% (combo) vs 15.8% (PHP alone); HR 0.34, p<0.001.
- Secondary endpoints: 2-yr OS 49.6% vs 22.1% (HR 0.39, p=0.006); ORR 76.3% vs 39.5% (p<0.001).
- Grade 3+ AEs higher in combo (81.6% vs 40.5%) but manageable; no new safety signals.